Atharva Karulkar – Immunoact

• Atharva Karulkar co-founded ImmunoACT in October 2018, aiming to innovate within the field of immunology and biotherapeutics.
• Under Atharva's leadership, ImmunoACT developed groundbreaking therapies focused on enhancing the immune system's capabilities against various diseases.
• ImmunoACT has navigated significant challenges related to research funding and regulatory approvals, which are common in the biotechnology sector.
• In July 2022, Atharva completed a doctoral program at the Indian Institute of Technology, Bombay, providing a strong academic backing to the scientific approach at ImmunoACT.
• The research conducted during the doctoral studies contributed valuable insights that informed the strategic direction of ImmunoACT's projects.
• Atharva's work has positioned ImmunoACT as a key player in the biotechnological landscape, attracting attention from industry experts and potential investors.
• Networking established through the academic and startup communities has led to collaborations that enhance ImmunoACT's research capabilities and market reach.
• ImmunoACT's therapies have shown promising results in early clinical trials, indicating a positive impact on patient health outcomes.
• Atharva's commitment to innovation and excellence has cultivated a dynamic company culture focused on scientific advancement and ethical entrepreneurship.

Professional Experience

Estimated Range: ₹0 – ₹1000+ Cr (approx. $0 – $120M+)

Based on publicly accessible filings, industry benchmarks, and leadership compensation patterns.

Official Email: Via Immunoact corporate communication desk.

Personal Contact: Not publicly disclosed.

What is Atharva Karulkar's net worth?
Estimated ₹0 – ₹1000+ Cr (approx. $0 – $120M+).

How can I contact them?
Through Immunoact's official communication channels.

Is this an official profile?
No — independently created using public data.

This profile is created for general informational purposes. All details are based on publicly accessible information and independent research. While accuracy is prioritized, content may not always reflect the latest updates.

Nothing here should be interpreted as investment, financial, or legal advice. The individual featured has not authored or endorsed this profile.

Personal information is intentionally withheld. For official matters, please use formal communication channels associated with the respective organization.

Affluense AI – Smarter Insights. Stronger Relationships with Affluents.

Last Updated: December 2025 · Published by Affluense AI (affluense.ai)